Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹786.15 - ₹1,475.70
Previous CloseN/A
Volume67.81K
Average Volume (3M)11.95K
Market Cap
₹307.90B
Enterprise Value₹184.75K
Total Cash (Recent Filing)₹1.58B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)84.4
Beta1.11
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.17
Shares Outstanding212,285,660
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,610.00Price Target Upside59.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)18.99
Revenue Forecast (FY)₹26.18B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Margin ExpansionVery high reported revenue growth with simultaneous margin expansion indicates the company is capturing demand and extracting operating leverage across services. That durable mix shift toward higher-margin development work supports sustainable profitability and reinvestment capacity over the medium term.
Integrated CRDMO Model With Multi-year Customer ProgramsAn end-to-end CRDMO model creates multi-year program continuity and cross-sell opportunities as molecules move from discovery to commercial supply. This structural client stickiness reduces revenue volatility and supports predictable, repeatable revenue streams over multiple years.
Conservative Balance Sheet And Improving ReturnsLow leverage and a stronger equity base provide financial flexibility to fund capex, scale manufacturing capacity, or pursue M&A without over-relying on debt. Rising ROE signals improving capital efficiency, which supports resilient long-term growth execution.
Bears Say
Persistent Negative Free Cash FlowSustained negative free cash flow despite revenue and margin gains points to a disconnect between accounting earnings and cash generation. Over time this can force reliance on external financing, restrict organic investment, and increase vulnerability if capital markets tighten.
Deteriorating FCF Growth And Weak Cash ConversionA sharp YoY decline in free cash flow and negative cash conversion relative to net income indicate rising reinvestment or working-capital absorption. If this trend persists it undermines the sustainability of margin gains and heightens refinancing or liquidity risk over the medium term.
Gross Margin Compression / Input-cost PressureA decline in gross margin signals exposure to higher input costs or pricing pressure in competitive manufacturing contracts. Persistent compression at the gross level can erode operating profit and cash flow unless offset by pricing, mix shift toward higher-value services, or productivity gains.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹786.15 and its highest was ₹1475.70 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹307.90B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 81 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on Aug 06, 2026. The company reported ₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹3.6 by -₹0.1.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,285,660 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹3.5 in its last earnings report, missing expectations of ₹3.6. Following the earnings report the stock price went up 1.572%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,610.00
▲(59.37% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―









